nach oben

Die Chirurgie

Erschienen in:

14.09.2021 | Hepatozelluläres Karzinom | Leitthema

Einfluss der Molekularpathologie auf die onkologische Chirurgie von Leber- und Gallengangstumoren

verfasst von: Mazen A. Juratli, Benjamin Struecker, Shadi Katou, M. Haluk Morguel, Univ.-Prof. Dr. med. Andreas Pascher

Erschienen in: Die Chirurgie | Ausgabe 11/2021

Einloggen, um Zugang zu erhalten

Zusammenfassung

Hintergrund

Die Molekularpathologie dient zunehmend der Therapiesteuerung in der Onkologie. Etwa 25 % aller hepatozellulären Karzinome (HCCs) und 50 % der Cholangiokarzinome (CCAs) weisen bekannte krebsrelevante Mutationen auf, deren Einfluss auf die Behandlung dieser Tumoren noch nicht ausreichend verstanden ist.

Ziel der Arbeit

Die Evaluation der aktuellen Literatur über die molekularpathologischen Fortschritte beim HCC/CCA und deren möglicher Einfluss auf die onkologische Chirurgie.

Material und Methoden

Zunächst erfolgte eine Zusammenfassung der in PubMed und clinitrials.gov verfügbaren Literatur über die aktuell bekannten molekularen Biomarker beim HCC/CCA. Anhand dieser Daten wird der mögliche Einfluss dieser Biomarker auf die onkologische Chirurgie diskutiert.

Schlussfolgerung

Molekularpathologische Untersuchungen können zur Unterstützung der Tumortypisierung und Dignitätsbestimmung von HCCs/CCAs eingesetzt werden. Prädiktive molekulare Biomarker konnten sich in der regulären Diagnostik noch nicht etablieren, können aber zur erweiterten Therapieplanung eingesetzt werden.

Park SE, Noh JM, Kim YJ, Lee HS, Cho JH, Lim SW et al (2019) EGFR mutation is associated with short progression free survival in patients with stage III non-squamous cell lung cancer treated with concurrent chemoradiotherapy. Cancer Res Treat 51(2):493–501PubMedCrossRef

Akinyemiju T, Abera S, Ahmed M, Alam N, Alemayohu MA, Allen C et al (2017) The burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global, regional, and national level: results from the global burden of disease study 2015. JAMA Oncol 3(12):1683–1691PubMedPubMedCentralCrossRef

Llovet JM, Kelley RK, Villanueva A, Singal AG, Pikarsky E, Roayaie S et al (2021) Hepatocellular carcinoma. Nat Rev Dis Primers 7(1):6PubMedCrossRef

Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A et al (2016) Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med 375:1823–1833PubMedCrossRef

Nöpel-Dünnebacke S, Conradi L‑C, Reinacher-Schick A, Ghadimi M (2020) Therapeutic relevance of molecular markers in colorectal cancer. Onkologe 26:685–697CrossRef

Duffy M, Harbeck N, Nap M, Molina R, Nicolini A, Senkus E et al (2017) Clinical use of biomarkers in breast cancer: updated guidelines from the European Group on Tumor Markers (EGTM). Eur J Cancer 75:284–298PubMedCrossRef

Pinyol R, Torrecilla S, Wang H, Montironi C, Piqué-Gili M, Torres-Martin M et al (2021) Molecular characterization of hepatocellular carcinoma in patients with non-alcoholic steatohepatitis. J Hepatol. https://doi.org/10.1016/j.jhep.2021.04.049CrossRefPubMed

Llovet JM, Montal R, Sia D, Finn RS (2018) Molecular therapies and precision medicine for hepatocellular carcinoma. Nat Rev Clin Oncol 15(10):599–616PubMedCrossRef

Boyault S, Rickman DS, De Reyniès A, Balabaud C, Rebouissou S, Jeannot E et al (2007) Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets. Hepatology 45(1):42–52PubMedCrossRef

10.

Lee J‑S, Heo J, Libbrecht L, Chu I‑S, Kaposi-Novak P, Calvisi DF et al (2006) A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells. Nat Med 12(4):410–416PubMedCrossRef

11.

Toffanin S, Hoshida Y, Lachenmayer A, Villanueva A, Cabellos L, Minguez B et al (2011) MicroRNA-based classification of hepatocellular carcinoma and oncogenic role of miR-517a. Gastroenterology 140(5):1618–1628.e16PubMedCrossRef

12.

von Felden J, Villanueva A (2020) Role of molecular biomarkers in liver transplantation for hepatocellular carcinoma. Liver Transpl 26(6):823–831CrossRef

13.

Solinas A, Calvisi DF (2016) Programmed death ligand 1 expression in hepatocellular carcinoma: a prognostic marker and therapeutic target for liver cancer? Hepatology 64(6):1847–1849PubMedCrossRef

14.

Li X‑S, Li J‑W, Li H, Jiang T (2020) Prognostic value of programmed cell death ligand 1 (PD-L1) for hepatocellular carcinoma: a meta-analysis. Biosci Rep 40(4):BSR20200459PubMedPubMedCentralCrossRef

15.

Heitzer E, Haque IS, Roberts CE, Speicher MR (2019) Current and future perspectives of liquid biopsies in genomics-driven oncology. Nat Rev Genet 20(2):71–88PubMedCrossRef

16.

von Felden J, Garcia-Lezana T, Schulze K, Losic B, Villanueva A (2020) Liquid biopsy in the clinical management of hepatocellular carcinoma. Gut 69(11):2025–2034CrossRef

17.

Chen VL, Xu D, Wicha MS, Lok AS, Parikh ND (2020) Utility of liquid biopsy analysis in detection of hepatocellular carcinoma, determination of prognosis, and disease monitoring: a systematic review. Clin Gastroenterol Hepatol 18(13):2879–2902.e9PubMedCrossRefPubMedCentral

18.

Chen J, Parkin D, Chen Q, Lu J, Shen Q, Zhang B et al (2003) Screening for liver cancer: results of a randomised controlled trial in Qidong, China. J Med Screen 10(4):204–209PubMedCrossRef

19.

European Association for the Study of the Liver (2018) EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 69(1):182–236CrossRef

20.

Heimbach JK, Kulik LM, Finn RS, Sirlin CB, Abecassis MM, Roberts LR et al (2018) AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology 67(1):358–380PubMedCrossRef

21.

Tzartzeva K, Obi J, Rich NE, Parikh ND, Marrero JA, Yopp A et al (2018) Surveillance imaging and alpha fetoprotein for early detection of hepatocellular carcinoma in patients with cirrhosis: a meta-analysis. Gastroenterology 154(6):1706–1718.e1PubMedCrossRef

22.

Marrero JA, Feng Z, Wang Y, Nguyen MH, Befeler AS, Roberts LR et al (2009) α‑fetoprotein, des‑γ carboxyprothrombin, and lectin-bound α‑fetoprotein in early hepatocellular carcinoma. Gastroenterology 137(1):110–118PubMedCrossRef

23.

Marrero JA, Kulik LM, Sirlin CB, Zhu AX, Finn RS, Abecassis MM et al (2018) Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American Association for the Study of Liver Diseases. Hepatology 68(2):723–750PubMedCrossRef

24.

Pons F, Varela M, Llovet JM (2005) Staging systems in hepatocellular carcinoma. HPB 7(1):35–41PubMedPubMedCentralCrossRef

25.

Llovet JM, De Baere T, Kulik L, Haber PK, Greten TF, Meyer T et al (2021) Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol 18(5):293–313PubMedCrossRef

26.

Samuel M, Chow PK, Chan Shih-Yen E, Machin D, Soo KC (2009) Neoadjuvant and adjuvant therapy for surgical resection of hepatocellular carcinoma. Cochrane Database Syst Rev 1:Cd1199

27.

Lee JH, Lee JH, Lim YS, Yeon JE, Song TJ, Yu SJ et al (2015) Adjuvant immunotherapy with autologous cytokine-induced killer cells for hepatocellular carcinoma. Gastroenterology 148(7):1383–1391.e6PubMedCrossRef

28.

Bruix J, Takayama T, Mazzaferro V, Chau GY, Yang J, Kudo M et al (2015) Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Oncol 16(13):1344–1354PubMedCrossRef

29.

Renner P, Da Silva T, Schnitzbauer AA, Verloh N, Schlitt HJ, Geissler EK (2021) Hepatocellular carcinoma progression during bridging before liver transplantation. BJS Open 5(2):zrab5PubMedPubMedCentralCrossRef

30.

Singal AG, Pillai A, Tiro J (2014) Early detection, curative treatment, and survival rates for hepatocellular carcinoma surveillance in patients with cirrhosis: a meta-analysis. PLoS Med 11(4):e1001624PubMedPubMedCentralCrossRef

31.

Lencioni R, Llovet JM, Han G, Tak WY, Yang J, Guglielmi A et al (2016) Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: the SPACE trial. J Hepatol 64(5):1090–1098PubMedCrossRef

32.

Meyer T, Fox R, Ma YT, Ross PJ, James MW, Sturgess R et al (2017) Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trial. Lancet Gastroenterol Hepatol 2(8):565–575PubMedCrossRef

33.

Kudo M, Han G, Finn RS, Poon RT, Blanc JF, Yan L et al (2014) Brivanib as adjuvant therapy to transarterial chemoembolization in patients with hepatocellular carcinoma: a randomized phase III trial. Hepatology 60(5):1697–1707PubMedCrossRef

34.

Struecker B, Morguel H, Pascher A (2020) Cholangiokarzinome–aktuelle Therapiestandards. Onkologe 26(3):238–245CrossRef

35.

Banales JM, Marin JJ, Lamarca A, Rodrigues PM, Khan SA, Roberts LR et al (2020) Cholangiocarcinoma 2020: the next horizon in mechanisms and management. Nat Rev Gastroenterol Hepatol 17(9):557–588PubMedPubMedCentralCrossRef

36.

Rizvi S, Khan SA, Hallemeier CL, Kelley RK, Gores GJ (2018) Cholangiocarcinoma—evolving concepts and therapeutic strategies. Nat Rev Clin Oncol 15(2):95PubMedCrossRef

37.

Patel AH, Harnois DM, Klee GG, LaRusso NF, Gores GJ (2000) The utility of CA 19‑9 in the diagnoses of cholangiocarcinoma in patients without primary sclerosing cholangitis. Am J Gastroenterol 95(1):204–207PubMedCrossRef

38.

Qin XL, Wang ZR, Shi JS, Lu M, Wang L, He QR (2004) Utility of serum CA19‑9 in diagnosis of cholangiocarcinoma: in comparison with CEA. World J Gastroenterol 10(3):427–432PubMedPubMedCentralCrossRef

39.

Marrero JA (2014) Biomarkers in cholangiocarcinoma. Clin Liver Dis (Hoboken) 3(5):101–103CrossRef

40.

Macias RIR, Kornek M, Rodrigues PM, Paiva NA, Castro RE, Urban S et al (2019) Diagnostic and prognostic biomarkers in cholangiocarcinoma. Liver Int 39(Suppl 1):108–122PubMedCrossRef

41.

Wan JCM, Massie C, Garcia-Corbacho J, Mouliere F, Brenton JD, Caldas C et al (2017) Liquid biopsies come of age: towards implementation of circulating tumour DNA. Nat Rev Cancer 17(4):223–238PubMedCrossRef

42.

Liang Z, Liu X, Zhang Q, Wang C, Zhao Y (2016) Diagnostic value of microRNAs as biomarkers for cholangiocarcinoma. Dig Liver Dis 48(10):1227–1232PubMedCrossRef

43.

Zhou J, Liu Z, Yang S, Li X (2017) Identification of microRNAs as biomarkers for cholangiocarcinoma detection: a diagnostic meta-analysis. Clin Res Hepatol Gastroenterol 41(2):156–162PubMedCrossRef

44.

Shigehara K, Yokomuro S, Ishibashi O, Mizuguchi Y, Arima Y, Kawahigashi Y et al (2011) Real-time PCR-based analysis of the human bile microRNAome identifies miR‑9 as a potential diagnostic biomarker for biliary tract cancer. PLoS One 6(8):e23584PubMedPubMedCentralCrossRef

45.

Al Ustwani O, Iancu D, Yacoub R, Iyer R (2012) Detection of circulating tumor cells in cancers of biliary origin. J Gastrointest Oncol 3(2):97–104PubMedPubMedCentral

46.

Yang JD, Campion MB, Liu MC, Chaiteerakij R, Giama NH, Ahmed Mohammed H et al (2016) Circulating tumor cells are associated with poor overall survival in patients with cholangiocarcinoma. Hepatology 63(1):148–158PubMedCrossRef

47.

Parsa N, Khashab MA (2019) The role of peroral cholangioscopy in evaluating indeterminate biliary strictures. Clin Endosc 52(6):556PubMedPubMedCentralCrossRef

48.

Voigtländer T, Gupta SK, Thum S, Fendrich J, Manns MP, Lankisch TO et al (2015) MicroRNAs in serum and bile of patients with primary sclerosing cholangitis and/or cholangiocarcinoma. PLoS ONE 10(10):e139305PubMedPubMedCentralCrossRef

49.

Wang LJ, He CC, Sui X, Cai MJ, Zhou CY, Ma JL et al (2015) MiR-21 promotes intrahepatic cholangiocarcinoma proliferation and growth in vitro and in vivo by targeting PTPN14 and PTEN. Oncotarget 6(8):5932–5946PubMedPubMedCentralCrossRef

50.

Forner A, Vidili G, Rengo M, Bujanda L, Ponz-Sarvisé M, Lamarca A (2019) Clinical presentation, diagnosis and staging of cholangiocarcinoma. Liver Int 39(Suppl 1):98–107PubMedCrossRef

51.

Valle JW, Borbath I, Khan SA, Huguet F, Gruenberger T, Arnold D (2016) Biliary cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 27(Suppl 5):v28–v37PubMedCrossRef

52.

Nakamura H, Arai Y, Totoki Y, Shirota T, Elzawahry A, Kato M et al (2015) Genomic spectra of biliary tract cancer. Nat Genet 47(9):1003–1010PubMedCrossRef

53.

Nepal C, O’Rourke CJ, Oliveira D, Taranta A, Shema S, Gautam P et al (2018) Genomic perturbations reveal distinct regulatory networks in intrahepatic cholangiocarcinoma. Hepatology 68(3):949–963PubMedCrossRef

54.

Ruys AT, Groot Koerkamp B, Wiggers JK, Klümpen HJ, ten Kate FJ, van Gulik TM (2014) Prognostic biomarkers in patients with resected cholangiocarcinoma: a systematic review and meta-analysis. Ann Surg Oncol 21(2):487–500PubMedCrossRef

55.

Liu CH, Huang Q, Jin ZY, Xie F, Zhu CL, Liu Z et al (2018) Circulating microRNA-21 as a prognostic, biological marker in cholangiocarcinoma. J Cancer Res Ther 14(1):220–225PubMedCrossRef

56.

Darwish Murad S, Kim WR, Harnois DM, Douglas DD, Burton J, Kulik LM et al (2012) Efficacy of neoadjuvant chemoradiation, followed by liver transplantation, for perihilar cholangiocarcinoma at 12 US centers. Gastroenterology 143(1):88–98.e3 (quiz e14)PubMedCrossRef

57.

Ethun CG, Lopez-Aguiar AG, Anderson DJ, Adams AB, Fields RC, Doyle MB et al (2018) Transplantation versus resection for hilar cholangiocarcinoma: an argument for shifting treatment paradigms for resectable disease. Ann Surg 267(5):797–805PubMedCrossRef

58.

Frosio F, Mocchegiani F, Conte G, Bona ED, Vecchi A, Nicolini D et al (2019) Neoadjuvant therapy in the treatment of hilar cholangiocarcinoma: review of the literature. World J Gastrointest Surg 11(6):279–286PubMedPubMedCentralCrossRef

59.

Zhang XF, Beal EW, Bagante F, Chakedis J, Weiss M, Popescu I et al (2018) Early versus late recurrence of intrahepatic cholangiocarcinoma after resection with curative intent. Br J Surg 105(7):848–856PubMedCrossRef

60.

Zhang XF, Beal EW, Chakedis J, Chen Q, Lv Y, Ethun CG et al (2018) Defining early recurrence of hilar cholangiocarcinoma after curative-intent surgery: a multi-institutional study from the US Extrahepatic Biliary Malignancy Consortium. World J Surg 42(9):2919–2929PubMedCrossRef

61.

Miura JT, Johnston FM, Tsai S, George B, Thomas J, Eastwood D et al (2015) Chemotherapy for surgically resected intrahepatic cholangiocarcinoma. Ann Surg Oncol 22(11):3716–3723PubMedCrossRef

62.

Malka D, Edeline J (2019) Adjuvant capecitabine in biliary tract cancer: a standard option? Lancet Oncol 20(5):606–608PubMedCrossRef

63.

Shroff RT, Kennedy EB, Bachini M, Bekaii-Saab T, Crane C, Edeline J et al (2019) Adjuvant therapy for resected biliary tract cancer: ASCO clinical practice guideline. J Clin Oncol 37(12):1015–1027PubMedCrossRef

64.

Stein A, Arnold D, Bridgewater J, Goldstein D, Jensen LH, Klümpen H‑J et al (2015) Adjuvant chemotherapy with gemcitabine and cisplatin compared to observation after curative intent resection of cholangiocarcinoma and muscle invasive gallbladder carcinoma (ACTICCA‑1 trial)-a randomized, multidisciplinary, multinational phase III trial. BMC Cancer 15(1):564PubMedPubMedCentralCrossRef

65.

Ben-Josef E, Guthrie KA, El-Khoueiry AB, Corless CL, Zalupski MM, Lowy AM et al (2015) SWOG S0809: a phase II intergroup trial of adjuvant capecitabine and gemcitabine followed by radiotherapy and concurrent capecitabine in extrahepatic cholangiocarcinoma and gallbladder carcinoma. J Clin Oncol 33(24):2617–2622PubMedCrossRef

66.

Jia AY, Wu JX, Zhao YT, Li YX, Wang Z, Rong WQ et al (2015) Intensity-modulated radiotherapy following null-margin resection is associated with improved survival in the treatment of intrahepatic cholangiocarcinoma. J Gastrointest Oncol 6(2):126–133PubMedPubMedCentral

67.

Plentz RR, Malek NP (2016) Systemic therapy of cholangiocarcinoma. Visc Med 32(6):427–430PubMedPubMedCentralCrossRef

68.

Lowery MA, Goff LW, Keenan BP, Jordan E, Wang R, Bocobo AG et al (2019) Second-line chemotherapy in advanced biliary cancers: a retrospective, multicenter analysis of outcomes. Cancer 125(24):4426–4434PubMedCrossRef

69.

Abou-Alfa G, Mercade TM, Javle M, Kelley R, Lubner S, Adeva J et al (2019) ClarIDHy: a global, phase III, randomized, double-blind study of ivosidenib (IVO) vs placebo in patients with advanced cholangiocarcinoma (CC) with an isocitrate dehydrogenase 1 (IDH1) mutation. Ann Oncol 30:v872–v873CrossRef

70.

Lowery MA, Abou-Alfa GK, Burris H (2017) Phase 1 study of AG-120, an IDH1 mutant enzyme inhibitor: results from the cholangiocarcinoma dose escalation and expansion cohorts. J Clin Oncol 132(2):3

71.

Javle M, Lowery M, Shroff RT, Weiss KH, Springfeld C, Borad MJ et al (2018) Phase II study of BGJ398 in patients with FGFR-altered advanced cholangiocarcinoma. J Clin Oncol 36(3):276–282PubMedCrossRef

72.

Yamamoto K, Ueno T, Kawaoka T, Hazama S, Fukui M, Suehiro Y et al (2005) MUC1 peptide vaccination in patients with advanced pancreas or biliary tract cancer. Anticancer Res 25(5):3575–3579PubMed

73.

Guo Y, Feng K, Liu Y, Wu Z, Dai H, Yang Q et al (2018) Phase I study of chimeric antigen receptor-modified T cells in patients with EGFR-positive advanced biliary tract cancers. Clin Cancer Res 24(6):1277–1286PubMedCrossRef

Titel: Einfluss der Molekularpathologie auf die onkologische Chirurgie von Leber- und Gallengangstumoren
verfasst von: Mazen A. Juratli
Benjamin Struecker
Shadi Katou
M. Haluk Morguel
Univ.-Prof. Dr. med. Andreas Pascher
Publikationsdatum: 14.09.2021
Verlag: Springer Medizin
Schlagwörter: Hepatozelluläres Karzinom
Pathologie
Hepatozelluläres Karzinom
Cholangiokarzinom
Cholangiokarzinom
Biomarker
Erschienen in: Die Chirurgie / Ausgabe 11/2021
Print ISSN: 2731-6971
Elektronische ISSN: 2731-698X
DOI: https://doi.org/10.1007/s00104-021-01495-6

Passend zum Thema

Synergien nutzen gegen Tumore

Magenkarzinom

Lungen- und Magentumore können dank Immuntherapien deutlich besser behandelt werden. Dennoch kommt es trotzdem weiterhin häufig zum Krankheitsprogress. Welche Therapieoptionen sich in der Zweitlinie am besten eignen, haben wir für Sie zusammengefasst.

Darmkrebsreihenuntersuchungen zeigen EU-weit Erfolge

Kolonkarzinom

In Europa haben viele Länder dem Darmkrebs mit Hilfe von Früherkennungsprogrammen den Kampf angesagt. Es gibt einen deutlichen Zusammenhang zwischen Inzidenz und Mortalität von Darmkrebs und der Zeitspanne seit Einführung von Reihenuntersuchungen.

GI-Tumore und die Rolle von Angiogenesehemmern

Content Hub

Entdecken Sie mit praxisrelevanten Patientenfällen, kompakten Studieninhalten, informativen Experteninterviews und weiteren spannenden Inhalten, wie Sie den vielseitigen Herausforderungen bei GI-Tumoren begegnen können. Hier erfahren Sie mehr! _{PP-RB-DE-2009}

Springer Medizin

Zusammenfassung

Hintergrund

Ziel der Arbeit

Material und Methoden

Schlussfolgerung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 11/2021

Behandlungsstrategien und Ergebnisse bei injektionsassoziierten inguinalen perivaskulären Abszessen bei intravenös Drogenabhängigen

Traumatische Gefäßverletzungen

Webinar zur S3-Leitlinie „Strategie zur Sicherung rationaler Antibiotikaanwendung im Krankenhaus“

Ein seltener Subtyp duodenaler neuroendokriner Tumore